Clinical Trial Update: Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial for relapsed or refractory acute myeloid leukemia sponsored by SGX Pharmaceuticals has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: SGX Pharmaceuticals, Inc. | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: TERMINATED